Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle

Phase 2positivepetrelintidePositive

AI Analysis

Summary

Zealand Pharma and Roche announced positive Phase 2 data for petrelintide, an amylin drug for obesity and diabetes treatment, positioning themselves as competitors to Eli Lilly in this market.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Importance:6/10

Sentiment:

0.60

Phase 2 dataamylin agonistobesitydiabetespartnershipcompetitive landscape

Related Companies

$ZEAL $RHHBY

Read the original article

Published by Endpoints News on October 8, 2026 2:41 PM

Read Original